61 results about "Matrix metalloproteinase 9" patented technology

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu which is a brand new sequence (D-Pyr is D-type pyridine alanine, D-Cys isD-type cysteine, and Bip is diphenyl alanine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

The invention discloses an application of curcumin in the preparation of a thyroid carcinoma therapeutic agent, and belongs to the technical field of curcumin pharmaceutical application. Curcumin can kill thyroid carcinoma cells specifically and has little influence on normal thyroid cells. Curcumin can promote the apoptosis of thyroid carcinoma cells, initiate the digestion of poly adenosine diphosphate-ribose polymerase (PARP), and significantly inhibit the expression of anti-apoptotic protein Bcl-2; meanwhile, curcumin can also inhibit the secretion of thyroid carcinoma cell matrix metalloproteinase-9 and the adhesion to extracellular matrix. Above results show that curcumin has good intervention effect on various links of proliferation, migration, and adhesion of thyroid carcinoma cells, and is applicable to the preparation of medicaments for treating thyroid carcinoma.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction to an organism. The sequence of the polypeptide is Pro-Arg-Cys-(D-Bip)-(D-Arg)-Gly-Glu which is a brand new sequence (D-Bip is D-type diphenyl alanine, and D-Arg is D-type arginine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (MMP9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.

The invention discloses a construction method of an enzyme-reponsive multifunctional nano-coating. The construction method comprises the following steps: firstly, immobilizing avidin molecules to the surface of dopamine-coated stainless steel; then, on the basis of specific recognition and binding effects between avidin and biotin, immobilizing biotinylated heparin/PEI nanoparticles to the surface of a material, and further binding high-concentration avidin molecules to residual biotin on the surface of a nanoparticle coating, so that a novel biotin binding site is introduced; then, continuing to assemble biotinylated enzyme-responsive polypeptide to the surfaces of the nanoparticles on the basis of an interaction between the biotin and the avidin; and finally, by virtue of an EDC/NHS/MES coupling agent, immobilizing SDF-1[alpha] to an amino terminal of the polypeptide in a covalent mode, so that the multifunctional nano-coating, which has a matrix metalloproteinase 9 responsive characteristic, is constructed. According to the construction method provided by the invention, by constructing a multifunctional layer, which has anti-coagulating and endothelial regeneration inducing capacities, on a titanium surface, blood compatibility and a damaged endothelial repair capacity of the material can be obviously improved.

The invention provides a molecular marker for diagnosing or treating glioma and applications thereof. Experimental studies show that the expression of microRNA-588 in glioma is significantly up-regulated in hypoxia state than in normoxia state. In vitro experiments show that the miR-588 can inhibit the invasive migration of glioma cells and VM formation ability. In order to clarify the molecular mechanism, further experiments find that Robo1 is a direct and functional related target of the miR-588 in glioma. The knocking out of the Robo1 inhibits the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), thereby inhibiting invasive migration of glioma and VM formation ability. Therefore, the miR-588 and the Robo1 can be used as a molecular marker for diagnosing or treating glioma.

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

A drug for inhibiting the production of matrix metalloproteinase-9 which contains leptomycin B or its derivative as the active ingredient can specifically inhibit the production of MMP-9 compared with MMP-2, furthermore, has an effect of inhibiting the production of MMP-9 even under stimulating the differentiation by adding calcium at a high concentration or adding TGF-β, and under stimulating for inducing inflammation by adding TNF-α or adding IL-2α.

The invention relates to application of micro peptide CIP2A-BP in treatment of cancer. From the prospective of translating horizontal IncRNA codes, the influence of the micro peptide on the malignantbiological behaviors of breast cancer cell transferring and migration is studied. By means of treatment of the targeted micro peptide CIP2A-BP, B56 gamma subunits of the micro peptide CIP2A-BP and PP2A are competitively bound with cell cancer genes CIP2A, and therefore PP2A activity is released, activation of a PI3K/AKT/NF kappa B access is inhibited, and consequently the expression level of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and EMT induced transcription factors Snail is reduced. It is proved through in-vitro and in-vivo experiments that migration and invasion of breast cancer cells can be obviously inhibited through micro peptide CIP2A-BP, and the micro peptide CIP2A-BP has clinical application value on breast cancer.

The invention relates to the field of natural pharmaceutical chemistry and discloses a chemical structure of a new honeysuckle chlorogenic acid ester saponin compound which is extracted and separated from lonicera macranthodes hand-mazz buds, and the compound has the structure as shown in the right formula. The invention further relates a preparation method of the compound and a use of the compound in the field of medicine, in particular to a use of the compound in preparation of cycloxygenase II inhibitors, matrix metalloproteinase-9 inhibitors or anti-tumor drugs.

The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-Arg-(D-Cys)-Bip-Arg-Gly-Glu (Bip is D-type diphenyl alanine, D-Cys is D-type cysteine), which is a brand new sequence. The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate ofan endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.

This invention relates to methods for assaying the presence and/or risk of endometrial cancer by measurement of levels of matrix metalloproteinase-2 and/or matrix metalloproteinase-9 in uterine washings. The method may be qualitative or quantitative, and is adaptable to large-scale screening and to clinical trials.

The invention discloses application of acetylcysteine in preparation of medicines for preventing and treating postoperative cognitive dysfunction and blood brain-barrier damage mediated encephalopathy and specifically discloses application of acetylcysteine in treatment of cognitive impairment after anesthesia and surgical trauma. Due to advanced application of the acetylcysteine before operative anesthesia, reduction of fear memory ability and new object recognition ability related to hippocampus after the anesthesia and operation can be obviously alleviated. The effect is specifically achieved by inhibiting a level of peripheral matrix metalloproteinase-9 through the acetylcysteine to protect the blood brain-barrier function and reducing the inflammatory factor up-regulation level of the hippocampus.

An application of the matrix metal proteinase (MMP) inhibitor, especially the inhibitor of 1(MMP1), 9 (MMP9) or 12 (MMP12), in preparing the medicines for preventing and/or treating piles is disclosed.

The invention relates to the field of medicaments, in particular to a polypeptide for inhibiting matrix metalloproteinase-9 and tumor necrosis factor kallikrein and reducing destroy on an organism by acute inflammatory reaction. A sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-(D-Cys)-Gly-Glu and is a brand new sequence, wherein Bip is biphenyl alanine, D-Pyr is D-type pyridine alanine, and D-cys is D-type cysteine; the activities of the matrix metalloproteinase-9 and the tumor necrosis factor kallikrein can be inhibited in vitro at the level of 1 micromole; the survival rate of mice undergoing endotoxic shock is increased during an in-vivo test; and the polypeptide has a potential novel medicament development value.

The invention provides a method for diagnosing ovarian cancer of subjects, which comprises the steps of: detecting MMP-9 content of samples from the subjects; analyzing the MMP-9 content; and confirming whether the subjects are suffered from ovarian cancer or not according to the analysis results. The invention also provides a kit for the diagnosis of ovarian cancer.

The invention relates to a skeletal muscle expression system cultivated in vitro that includes building the expression gene of the aim gene, expressing carrier transferring host cell group and filtering, expressing the aim gene in host cell and separating and purifying the expression product. The feature is that the expression carrier is constructed on the base of pcDAN3.0 and carrying myc10 testing mark and 6*his purified mark, and inserting 9(MMP-9) signal sequence into expression carrier. QM7 cell is adopted as host cell expression albumen. Non-serum separating culture medium suited to QM7 cell separating is filtered. The cost of culture medium is low and is benefit for the late purifying stage, and lays a strong foundation for large scale manufacturing medicine that uses PEX as rebuilding albumen.

The invention provides an application of a lignans compound in preparation of an anti-hepatic fibrosis medicine. In-vitro, in-vivo and molecular-level tests prove that the lignans compound has strongeffect of inhibiting proliferation of hepatic stellate cells and resisting the hepatic fibrosis, and also has lower IC50 value to matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9) and transforming growth factor-beta1 (TGF-beta1). The lignans compound can be combined with the substances mentioned hereinabove and can inhibit the bioactivities of the substances, so that the lignanscompound can be used as an anti-hepatic fibrosis medicine.

The invention discloses an mPEG-SC5K modified matrix metalloproteinase-9 inhibitor polypeptide P2 and application thereof, and belongs to the technical field of polypeptide medicines. The polypeptide disclosed by the invention has a sequence of mPEG-SC5K-Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro. Due to mPEG-SC5K modification, the polypeptide has an effect of inhibiting the activity of matrix metalloproteinase-9, has pharmacokinetic properties which are greatly improved compared with those of P2, and can be used for treatment of acute inflammations and autoimmune diseases taking overexpression and over-activity of the matrix metalloproteinase-9 as characteristics. The mPEG-SC5K modified polypeptide P2 designed in the invention is prepared by a synthetic method. The mPEG-SC5K modified polypeptide P2 achieves the effects of increasing the survival rate of endotoxic shock mice in acute inflammation tests and improving the paralysis degree of model mice in multiple sclerosis animal tests, and has potential new drug development value.

The present invention relates to the CGlc compound for inhibiting the expression and activation of MMP-9 in HT1080 and the MMP-9 inhibitor comprising the CGlc compound as an effective ingredient, which can inhibits the expression of AP-1 in Ht1080 to effectively inhibit the expression and activation of MMP-9 such that it is effectuated in treating a wound, metastasis, rheumatoid arthritis, inflammation, hyperparathyroidism, diabetes, cornel ulcer, osteoporosis, stomach ulcer, trauma, pimple, burn, periodontal disease, arteriosclerosis or fracture.